Търсене на изпитвания

Намерени 4,436 изпитвания Стр. 97 от 222

Набира участници Фаза 1/2

Safety and Efficacy of AGN-INM176 in Prostate Patients With Rising PSA

Prostate Cancer

This Phase I/II open-label trial aims to evaluate the safety and efficacy of the herbal supplement INM176 in patients with a history of prostate cancer or low-risk disease under active surveillance. The study will determine the recommended Phase II dose (RP2D) and assess the efficacy of INM176 in stabilizing or decreasing plasma PSA levels in post-radical prostatectomy (RP) and post-radiation therapy (RT) patients with rising PSA levels.

Начало: 07.05.2025 Край: 01.05.2028 Възраст: от 40 г.

United States Milton S. Hershey Medical Center NCT06600698

Набира участници Фаза 4

Ocular Assessments in Patients Treated With Tivdak® in Recurrent or Metastatic Cervical Cancer

Cervical Cancer

TIVDAK is used for the treatment of cervical cancer that has come back after chemotherapy. Chemotherapy is a treatment that uses medicines to stop the growth of cancer cells. This is done either by killing the cells or by stopping them from growing. The purpose of this study is to learn about possible side effects of TIVDAK, specially to any side effect that is related to the eye. A side effect is anything a medicine does to your body that is not part of how the medicine treats disease. * This study is seeking for participants who: Are willing to take all the required eye tests * Have not received TIVDAK before * Do not have any active eye issues. Participants will receive TIVDAK once every 3 weeks as an infusion that will be injected into the vein. Participants will visit an eye care provider at 3 stages: * before starting the treatment, * before each of the first 9 infusions * then monthly for 3 months after they stop taking TIVDAK. Treatment with TIVDAK will continue until it is not working anymore against the participant's cancer.

Начало: 07.05.2025 Край: 13.12.2028 Възраст: от 18 г.

Puerto Rico, United States Pfizer NCT06952660

Набира участници

Microcurrent Stimulation Therapy for Intermediate to Advanced Nonexudative Age-related Macular Degeneration

Age-Related Macular Degeneration Age-related Macular Degeneration (ARMD) Intermediate AMD Geographic Atrophy Secondary to Age-related Macular Degeneration

The goal of this clinical trial is to characterize the safety and effectiveness of the i-Lumen AMD transpalpebral microcurrent device and therapy in patients with intermediate to advanced nonexudative AMD. Participants will: * Undergo an initial loading regimen, followed by 7 maintenance over the course of 11 months. * Participants will return monthly through Month 14 (3 months post-last treatment) for evaluation and monitoring.

Начало: 07.05.2025 Край: 31.12.2029 Възраст: от 60 г. Лечение

Australia, New Zealand, United Kingdom +1 i-Lumen Scientific AUS PTY LTD NCT06662162

Набира участници Фаза 2/3

Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy: Starting Immunoglobulin (Start Ig)

Myeloma Non Hodgkin's Lymphoma Leukemia

This study is being conducted to find out how safe and effective different strategies of infection prevention are in comparison to each other, for preventing infection in patients with blood cancers. The best way to find out this information is to directly compare the effect of different treatment strategies in patients with blood cancers. We want to know how these different treatments impact on your health and your use of healthcare services. This research project uses an Adaptive Platform Design. This design allows the researchers to compare multiple infection prevention strategies within the same trial at the same time (rather than running separate trials), to analyse results as the trial occurs and to add new research questions during the course of the trial. The treatments that you may receive as part of the study will be determined by which domain(s) of the platform you participate in. By combining data collected within each domain as part of the platform, the researchers can investigate and compare treatment strategies and infection outcomes across a broader range of participants.

Начало: 07.05.2025 Край: 31.03.2027 Възраст: от 18 г. Лечение

Australia Monash University NCT07202078

Набира участници Фаза 1/2

Safety of HRX215 in Patients After Minor and Major Liver Resection

Liver Resection Colorectal Carcinoma Liver Metastases

The goal of this clinical trial is to learn if HRX215 is safe, tolerable and active in adults who have undergone liver resection due to colorectal carcinoma metastases. The objectives are: 1. to learn about the safety and tolerability of HRX215 2. to learn about how the body absorbs, distributes, and gets rid of HRX215. 3. to learn about clinical activity of HRX215 Researchers will compare HRX215 to a placebo (a look-alike substance that contains no drug) to investigate safety, tolerability and clinical activity in participants taking HRX215.

Начало: 06.05.2025 Край: 31.12.2027 Възраст: 18–75 г.

Israel, United States HepaRegeniX GmbH NCT06638502

Набира участници Фаза 3

Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial - Part 2

Intracerebral Hemorrhage

The objective of the rFVIIa for Acute Hemorrhagic Stroke Administered at Earliest Time (FASTEST) Trial is to establish the first treatment for acute spontaneous intracerebral hemorrhage (ICH) within a time window and subgroup of patients that is most likely to benefit. The central hypothesis is that rFVIIa, administered within 120 minutes from stroke onset with an identified subgroup of patients most likely to benefit, will improve outcomes at 90 days as measured by the Modified Rankin Score (mRS) and decrease ongoing bleeding as compared to standard therapy. FASTEST Part 2 is an extension of the FASTEST Trial where the subgroups include those treated within 2 hours with a positive spot sign on a baseline CT angiogram or patients treated within 90 minutes of stroke onset, with or without a positive spot sign.

Начало: 06.05.2025 Край: 01.06.2029 Възраст: 18–80 г.

Canada, Germany, Japan +3 Joseph Broderick, MD NCT07227246

Набира участници

Ultrathin Strut Sirolimus-eluting Stent With Bioabsorbable Polymer in Patients Receiving Chronic Oral Anticoagulation

Coronary Artery Disease Ischemic Heart Disease

Patients receiving chronic oral anticoagulation with indication for percutaneous coronary revascularization with stent implantation, and needing for antiplatelet therapy, are at high risk of bleeding. The new generation of ultrathin strut sirolimus-eluting stent with bioabsorbable polymer allow for shorter antiplatelets regimens and could be a good option for this high-bleeding risk patients.

Начало: 06.05.2025 Край: 31.03.2029 Възраст: от 18 г.

Spain Fundación EPIC NCT06863155

Набира участници Фаза 2/3

Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Platform Trial (RATIONAL-PT)

Myeloma Non-Hodgkin's Lymphoma Leukemia

This is an adaptive platform study to find out how safe and effective different strategies are in comparison to each other, for preventing infection in patients with blood cancers. It is a comparison between Immunoglobulin and antibiotics use.

Начало: 06.05.2025 Край: 31.03.2027 Възраст: от 18 г. Лечение

Australia Monash University NCT07202052

Набира участници Фаза 1/2

A Study of LM-168 as a Single Agent or in Combination With Toripalimab in Subjects With Advanced Solid Tumours

Advanced Solid Tumours

For phase I ,this study is to assess the safety and tolerability, obtain the recommended phase 2 dose (RP2D) and/or Maximum Tolerated Dose (MTD) for LM-168 as a single agent or in combination with toripalimab in subjects with advanced solid tumours. For phase II ,this study is to assess the preliminary anti-tumour activity of LM-168 as a single agent or in combination with toripalimab measured by objective response rate (ORR) in subjects with advanced solid tumours.

Начало: 06.05.2025 Край: 01.02.2028 Възраст: от 18 г. Лечение

Australia, China LaNova Medicines Limited NCT06868199

Набира участници

CorWave LVAS FIH Study

Advanced Heart Failure

The study is a prospective, multi-center, non-randomized trial to evaluate the safety and effectiveness of the CorWave LVAS for the treatment of advanced heart failure patients.

Начало: 06.05.2025 Край: 01.05.2028 Възраст: 18–75 г. Лечение

Australia CorWave NCT06907017

Набира участници Фаза 3

Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

NSCLC (Non-small Cell Lung Cancer) Non-Small Cell Lung Cancer NSCLC NSCLC (Non-small Cell Lung Carcinoma) +1

The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to docetaxel.

Начало: 06.05.2025 Край: 01.12.2030 Възраст: от 18 г. Лечение

Australia, Belgium, France +16 Revolution Medicines, Inc. NCT06881784

Набира участници Фаза 3

Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma

Hepatocellular Carcinoma

This is a Phase III, randomised, open-label, sponsor-blinded, 3-arm, multicentre, global study assessing the efficacy and safety of rilvegostomig in combination with bevacizumab with or without tremelimumab compared to atezolizumab in combination with bevacizumab. This study will be conducted in participants with advanced HCC who are not amenable to curative therapy or locoregional therapy

Начало: 06.05.2025 Край: 14.03.2030 Възраст: от 18 г. Лечение

Australia, Brazil, Canada +16 AstraZeneca NCT06921785

Набира участници Фаза 2/3

Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Immunoglobulin Stopping or Extension (Stop Ig)

Myeloma Leukemia Non Hodgkin's Lymphoma

Начало: 06.05.2025 Край: 31.03.2027 Възраст: от 18 г. Лечение

Australia Monash University NCT07202091

Набира участници Фаза 3

A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions

Myelodysplastic Syndromes

The main aim of this study is to find out how well elritercept works in lowering the need for RBC transfusions. Other aims are to learn how well elritercept works in reducing the need for RBC transfusions over longer periods of time or in adults with high transfusion needs. The study will also check on how safe elritercept is and how well it is tolerated.

Начало: 06.05.2025 Край: 01.05.2032 Възраст: от 18 г. Лечение

Australia, Brazil, Bulgaria +22 Takeda NCT06499285

Набира участници

Cancer Survivors Program

Prostate Cancer Patients Breast Cancer Patients

The questionnaire for assessment of adverse events after completion of cancer treatment, which is being piloted at the Masaryk Memorial Cancer Institute, aims to detect a wide range of adverse effects early on, thus facilitating adequate intervention and planning of follow-up care for all cancer survivors.

Начало: 05.05.2025 Край: 31.12.2026 Възраст: от 18 г.

Czechia Masaryk Memorial Cancer Institute NCT07253987

Набира участници Фаза 1/2

STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers and as Monotherapy in Participants With Selected Sarcomas

Solid Tumor Sarcoma Leiomyosarcoma Dedifferentiated Liposarcoma

This early phase oncology trial will be conducted at various study centers to investigate the safety, tolerability, and antitumor activity of STC-15 (a METTL3 inhibitor) in combination with toripalimab (anti- programmed cell death 1 \[PD-1\]) in advanced unresectable or metastatic tumors. The Phase 2 Monotherapy part is an open-label, non-randomized, multicenter Simon's 2-stage design that investigates the safety, tolerability, and antitumor activity of STC-15 in participants with selected, relapsed sarcomas subtypes, dedifferentiated (DD) liposarcoma and leiomyosarcoma (uterine and non-uterine).

Начало: 05.05.2025 Край: 29.06.2028 Възраст: от 18 г.

United States STORM Therapeutics LTD NCT06975293

Набира участници Фаза 2

WISPer: Evaluation of MTX-463 in Participants With Idiopathic Pulmonary Fibrosis (IPF)

Idiopathic Pulmonary Fibrosis

A Phase 2a, Randomized, Double-blind, Placebo-Controlled Study of the Safety and Efficacy of MTX-463 in Participants with Idiopathic Pulmonary Fibrosis (IPF)

Начало: 05.05.2025 Край: 01.08.2027 Възраст: от 40 г. Лечение

Argentina, Australia, Belgium +9 Mediar Therapeutics NCT06967805

Набира участници Фаза 2

Clonal Dynamics of Chronic Lymphocytic Leukaemia Treated With Pirtobrutinib After Previous Treatment With Zanubrutinib

Chronic Lymphocytic Leukemia

This is a multicentre single-arm prospective phase II trial evaluating pirtobrutinib in the treatment of relapsed/refractory (R/R) Chronic Lymphocytic Leukaemia (CLL) patients who have previously received zanubrutinib, and to specifically evaluate Bruton Tyrosine Kinase (BTK) mutational status (clonal dynamics) before, during and after treatment with pirtobrutinib.

Начало: 05.05.2025 Край: 01.05.2031 Възраст: от 18 г. Лечение

Australia Peter MacCallum Cancer Centre, Australia NCT06812715

Набира участници Фаза 3

An international, multicenter, randomized, double-blind, phase 3 pivotal registrational clinical study of APG-2575 (Lisaftoclax) combined with azacitidine in elderly patients with newly diagnosed acute myeloid leukemia (GLORA-3)

Acute myeloid leukemia

Trial status: Authorised Event-free survival (EFS): The interval from the date of randomization to the time point when any of the following “events” occur (whichever occurs first): • Progressive disease; • Disease recurrence after CR/CRi/CRh/MLFS; • Death of any cause (including but not limited to death caused by leukemia or therapeutic drugs); • CR/CRi/CRh/MLFS is not achieved after at least 6 treatment cycles., Complete response (CR) rate: The proportion of patients with complete response in the total analysis population., Overall response rate (ORR): The proportion of patients who have achieved CR, CRi, CRh, MLFS and PR in total analysis population., Composite complete response (CRc) rate: The proportion of patients who have achieved CR, CRi and CRh in total analysis population., Time to response (TTR): The interval from the date of randomization to the date of the first CR, CRi, or CRh., Duration of response (DOR): The interval from the date of confirming response (CR/CRi/CRh) to the date of disease recurrence or death of any cause (whichever occurs first). DOR will be calculated for patients with the best response of CR, CRh and CRi separately., Safety and tolerability of subjects: Treatment emergent adverse events (TEAEs) and treatment related adverse events (TRAEs) will be evaluated., Population pharmacokinetic (Pop PK) parameters of APG-2575., Results of EORTC QLQ C30 (V3) and EuroQol 5-Dimension (EQ-5D) questionnaire. Overall survival (OS): Interval between the date of randomization to the date of death of any cause. Survival time will be censored at the latest known survival date of the subject if death cannot be confirmed.

Начало: 05.05.2025 Възраст: от 18 г.

Italy, Poland, Spain Ascentage Pharma Group Inc. 2024-516436-10-00

Набира участници Фаза 1/2

A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer

Advanced Lung Cancer

This study aims to investigate the combination of BNT324, a B7-H3 antibody-drug conjugate (ADC) with BNT327, a programmed death-ligand 1 (PD-L1) and vascular endothelial growth factor (VEGF) bispecific antibody, in participants with advanced/metastatic or relapsed/progressive small cell lung cancer (SCLC) and non small cell lung cancer (NSCLC).

Начало: 02.05.2025 Край: 01.06.2031 Възраст: от 18 г. Лечение

Australia, China, Taiwan +3 BioNTech SE NCT06892548

1 … 95 96 97 98 99 … 222